Apyx Medical Inc

Apyx Medical Inc(APYX)股票分析

$3.080

+0.082 (+2.67%)收盤時

Loading chart…
High
3.220
Open
3.010
VWAP
3.10
Vol
115.65K
Mkt Cap
48.85M
Low
3.000
Amount
358.51K
EV/EBITDA, TTM
-17.72

Apyx Medical, Inc., formerly Apyx Medical Corporation, is a surgical aesthetics company. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs.

AI analysis of Apyx Medical Inc (APYX)

buy

Apyx Medical Corp is a good buy right now due to its recent earnings performance and positive growth outlook. The current price is $3.08, significantly lower than the analyst price target of $6, indicating a potential upside of 94%. Additionally, the company reported a 33% year-over-year revenue increase in Q1 2026, reaching $12.5 million, and raised its 2026 revenue guidance to between $59 million and $60 million, showcasing strong market confidence. However, the main risk is the negative net income, which was -$3.24 million in Q2 2026, indicating ongoing losses that investors should monitor closely.

估值指標

The current forward P/E ratio for Apyx Medical Inc (APYX) is 72.46, compared to its 5-year average forward P/E of 2.00.

Forward P/E

Strongly Overvalued
5Y Average P/E
2.00
Current P/E
72.46
高估
30.50
低估
-26.49

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-10.15
Current EV/EBITDA
-17.72
高估
30.02
低估
-50.32

Forward P/S

Fair
5Y Average P/S
2.73
Current P/S
1.91
高估
4.95
低估
0.52

Alphio AI Price Scenarios for APYX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%APYX

$1.80

情境價格

B

Base

Base · 50%APYX

$1.74

情境價格

B

Bear

Bear · 25%APYX

$1.70

情境價格

Whales holding APYX

N

Nantahala Capital Management, LLC

+ HoldingAPYX

+9.23%

3M Return

事件時間軸

2026-08-06 (ET)

17:00:00

Company Expects Operating Expenses Below $45 Million for 2026

17:00:00

AYON Reports Q2 Revenue of $13.88M, Beating Expectations

2026-05-07 (ET)

07:20:00

Company Reports Q1 Revenue of $12.49M, Exceeding Expectations

07:20:00

Company Confirms FY26 Operating Expenses Below $45M

2026-03-10 (ET)

07:10:00

Company Expects Total Revenue of $57.5M to $58.5M for 2026

資訊

APYX FAQ — answered by Alphio AI

Apyx Medical, Inc., formerly Apyx Medical Corporation, is a surgical aesthetics company. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Apyx Medical Corp is a good buy right now due to its recent earnings performance and positive growth outlook. The current price is $3.08, significantly lower than the analyst price target of $6, indicating a potential upside of 94%. Additionally, the company reported a 33% year-over-year revenue increase in Q1 2026, reaching $12.5 million, and raised its 2026 revenue guidance to between $59 million and $60 million, showcasing strong market confidence. However, the main risk is the negative net income, which was -$3.24 million in Q2 2026, indicating ongoing losses that investors should monitor closely.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始